A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Budapest III, Debrecen, Kaposvár, Pécs, Szeged, Szolnok és Veszprém, MagyarországSee the 8 sites
- Phase
- 3. fázis
Where in Magyarország
- Obudai Egeszsegugyi Centrum Kft.Budapest III, MagyarországNo longer taking part
- Derma-B Kft.Debrecen, MagyarországNo longer taking part
- University of DebrecenDebrecen, MagyarországNo longer taking part
- Somogy Vármegyei Kaposi Mór Oktató KórházKaposvár, MagyarországNo longer taking part
- University of PecsPécs, MagyarországNo longer taking part
- University of SzegedSzeged, MagyarországNo longer taking part
- Allergo-Derm Bakos KftSzolnok, MagyarországNo longer taking part
- Medmare Bt.Veszprém, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen - Cilag International
- Trial code
- EU 2023-505121-14-00
- Record updated
- 2026. július 16.
- Original description
To evaluate the efficacy of JNJ-77242113 compared with placebo in participants with moderate to severe plaque psoriasis.Read full original descriptionShow less
To evaluate the efficacy of JNJ-77242113 compared with placebo in participants with moderate to severe plaque psoriasis.
Inclusion: ≥18 years of age at the screening visit; Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention; Total BSA ≥10% at screening and baseline; Total PASI ≥12 at screening and baseline; Total IGA ≥3 at screening and baseline.
Exclusion: Current drug-induced psoriasis; Major surgical procedure, within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study; A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances; Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention; Nonplaque form of psoriasis.